Table 1 Demographic, baseline, and disease characteristics of patients with leiomyosarcoma
Characteristic | Eribulin (n = 157) | Dacarbazine (n = 152) | Total (N = 309) |
|---|---|---|---|
Median age (minimum, maximum), years | 57 (28, 76) | 56 (24, 77) | 57 (24, 77) |
Age group, n (%), years | |||
<65 | 123 (78) | 124 (82) | 247 (80) |
≥65 | 34 (22) | 28 (18) | 62 (20) |
Sex, n (%) | |||
Male | 29 (18) | 31 (20) | 60 (19) |
Female | 128 (82) | 121 (80) | 249 (81) |
Race, n (%) | |||
White | 110 (70) | 117 (77) | 227 (74) |
African American | 6 (4) | 4 (3) | 10 (3) |
Asiana | 14 (9) | 12 (8) | 26 (8) |
Otherb | 27 (17) | 19 (12) | 46 (15) |
ECOG PS, n (%) | |||
0 | 76 (48) | 66 (43) | 142 (46) |
1 | 80 (51) | 79 (52) | 159 (52) |
2 | 1 (1) | 7 (5) | 8 (3) |
Histology subcategory, n (%) | |||
Uterine | 68 (43) | 63 (41) | 131 (42) |
Nonuterine | 88 (56) | 89 (59) | 177 (57) |
Tumour grade, n (%) | |||
High | 112 (71) | 113 (74) | 225 (73) |
Intermediate | 45 (29) | 37 (24) | 82 (27) |
Not done | 0 | 2 (1) | 2 (1) |
Geographic region, n (%) | |||
USA and Canada | 62 (40) | 61 (40) | 123 (40) |
Western Europe, Australasia, Israel | 70 (45) | 68 (45) | 138 (45) |
Eastern Europe, Latin America, Asia | 25 (16) | 23 (15) | 48 (16) |
Median age at diagnosis (minimum, maximum), years | 53.0 (24, 75) | 52.5 (23, 75) | 53.0 (23, 75) |
Previous anticancer therapy,c n (%) | |||
0 | 0 | 0 | 0 |
1 | 2 (1) | 1 (1) | 3 (1) |
2 | 76 (48) | 70 (46) | 146 (47) |
3 | 44 (28) | 44 (29) | 88 (28) |
4 | 17 (11) | 25 (16) | 42 (14) |
>4 | 18 (12) | 12 (8) | 30 (10) |
